A second and important issue raised by Ritvo and Ritvo involves the effect of the new criteria on the utility of previously collected phenotypic and genetic ASD samples. They speculate that the changes in diagnostic criteria will make these samples “incompatible and unusable.” The authors assume that some of the existing cases will lose their ASD classification. However, our study results indicate that this is unlikely to be true. The new DSM-5 criteria now explicitly state that individuals with a well-informed clinical diagnosis of any of the previous PDD subtypes, including PDD-NOS and Asperger's disorder, do not have to be rediagnosed but are assumed to fall under the new larger category of ASD. Importantly, the revisions in DSM-5 provide researchers and clinicians an alternative system for coding dimensions both within ASD and from other areas, including intellectual disabilities, language disorders, and other disorders such as attention deficit hyperactivity disorder, through clinical specifiers. This system should result in more accurate and meaningful descriptions of individuals (see Grzadzinski et al. ).